This article aims to shed light on the multifaceted aspects of Wegovy side effects, offering a comprehensive understanding for individuals considering or currently using this medication
Charbonneau DE, Hanson ED, Ludlow AT, Delmonico MJ, Hurley BF, Roth SM
Accordingly, currently ongoing trials in HF (HFpEF) with the GLP-1 RA semaglutide (2.4 mg for once-weekly subcutaneous injection, i.e., the dose approved for weight management) enrols people with obesity with (STEP-HFpEF DM trial
The results demonstrated clear superiority over placebo across all measured endpoints
Currently, the evidence is largely anecdotal, with some users reporting anxiety or depression
Here's what to know for each